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Background: Several newer oral anti-Xa (Rivaroxaban, Apixaban and Edoxaban) and an oral antithrombin agent ( Dabigatran) are clinically used 
for the management of post surgical thrombosis and atrial fibrilation. Some of these agents are developed for acute coronary syndrome. While 
effective in their respective dosing, these agents reportedly exhibit different safety profiles in experimental animals and clinical trials. The purpose of 
this study was to investigate their differential effects on the coagulation and fibrinolytic process to explain these differences.
Methods: Pooled plasma samples from normal healthy volunteers (n=50) and liver disease patients (n=50) were supplemented at varying 
concentrations with Dabigatran and Rivaroxaban (0-2.5 ug/ml). Such parameters as the prothrombin time, partial thromboplastin time, Heptest 
time, thrombin time and prothrombin induced clotting time and thrombin generation inhibition were measured. Such fibrinolytic parameters as 
plasminogen, antiplasmin, plasminogen activator inhibitor, thrombin activatable fibrinolytic inhibitor and the activation of protein C were measured. 
Thrombin mediated activation of factor XIII, VIII, and V were also studied.
Results: In the normal and liver disease plasma, both the Dabigatran and Rivaroxaban produced concentration dependent anticoagulant 
responses. The responses in the liver disease patients were markedly stronger than by both agents. However, Dabigatran produced relatively 
stronger anticoagulant responses than Rivaroxaban. In the thrombin generation assays Rivaroxaban produced stronger effects in both systems. 
Dabigatran also produced inhibition of TAFI and protein C activation in both systems. Dabigatran also inhibited not only thrombin but also thrombin-
thrombomodulin dependant activation processes.
Conclusion: Thus the major differences between the Dabigatran and Rivaroxiban is the inhibitory effect on the target enzyme, thrombin generation 
and it’s regulatory actions on such enzymes as the XIIa,VIIIa and Va and protein C activation. Such differences may contribute to the differential 
therapeutic profile of these agents and require additional basic and clinical studies.
